Humans have never been selectively bred the way livestock or crops have, but modern reproductive technology has made it possible for prospective parents to screen embryos for specific genetic traits and, in experimental settings, to edit embryonic DNA directly. The phrase “human breeding” today refers less to any organized program and more to a constellation of tools, from preimplantation genetic testing to CRISPR gene editing, that give individuals some degree of influence over which genetic variants their children carry. These tools raise scientific questions about how much control over traits is actually achievable and ethical questions about who gets to decide what counts as a desirable genome.
From State-Run Eugenics to Parental Choice
For most of the twentieth century, “selective human breeding” meant state-sponsored eugenics: forced sterilizations, restrictive marriage laws, and institutional segregation justified by pseudoscientific ideas about racial fitness. That era left deep scars and rightly discredited the notion that governments should dictate who reproduces. But the underlying impulse to shape offspring’s genetic makeup did not disappear. It migrated into the private sphere. Today’s version is driven not by government mandates but by individual parents using reproductive technologies, genetic testing, and eventually, genetic engineering to fulfill their own reproductive goals.1PubMed Central. From Public Eugenics to Private Eugenics: What Does the Future Hold? The shift from public to private eugenics changes who holds power, but it does not automatically resolve the ethical tensions. It simply relocates them from legislatures to fertility clinics.
How Preimplantation Genetic Testing Works
The most widely used tool for influencing offspring genetics is preimplantation genetic testing, or PGT. During an IVF cycle, embryos are biopsied at the blastocyst stage, and cells are analyzed for genetic abnormalities before transfer to the uterus. PGT for monogenic disorders (PGT-M) can identify embryos carrying mutations responsible for conditions like cystic fibrosis, sickle cell disease, or Huntington’s disease. In theory, PGT-M is available for any single-gene disorder where the causative mutation has been identified.2PubMed Central. Preimplantation Genetic Testing for Monogenic Disorders Over the last decade, a shift from customized lab protocols to generic workflows using whole genome amplification followed by SNP arrays or next-generation sequencing has shortened wait times for couples and reduced laboratory workload considerably.
A parallel form, PGT for aneuploidies (PGT-A), screens embryos for chromosomal abnormalities such as extra or missing chromosomes. Together these technologies have become routine in many IVF clinics. Their success at preventing devastating single-gene conditions is well documented, and the underlying science is relatively straightforward: if a mutation follows a clear inheritance pattern, you can test for it and choose an embryo that does not carry it.3PubMed Central. Evolution and Utility of Preimplantation Genetic Testing for Monogenic Disorders in Assisted Reproduction – A Narrative Review
Polygenic Screening and Its Limits
Where things get murkier is with polygenic traits, which are the ones most people think of when they imagine “selecting” for intelligence, height, or athletic ability. These traits are influenced by hundreds or thousands of genetic variants, each contributing a tiny effect, plus a large role for environment. Companies now market polygenic embryo screening directly to fertility patients, generating risk scores that estimate an embryo’s genetic susceptibility to conditions like heart disease, diabetes, or schizophrenia, and sometimes non-disease traits as well.4PubMed Central. Choosing Your “Healthiest” Embryo After Dobbs: Polygenic Screening and Distinctive Challenges for Truth in Advertising and Informed Consent The marketing often encourages patients to “choose your healthiest embryo” and “protect your future child from genetic risks.”
The problem is that the actual predictive power of these scores for embryo selection is extremely limited. Mathematical modeling has shown negligible utility for non-disease traits like height and IQ, and even for disease traits like Crohn’s disease and schizophrenia the gains are small.5PubMed Central. Polygenic risk score for embryo selection—not ready for prime time Companies advertising these services commonly present the benefit as a difference between the highest-risk and lowest-risk embryos in a batch, rather than between two average embryos, which inflates the apparent advantage. A detailed analysis in the New England Journal of Medicine highlighted many factors that lower the predictive power of polygenic scores when applied to embryo selection, including the small number of embryos typically available in an IVF cycle and the poor transferability of scores across ethnic backgrounds.6PubMed Central. Problems with Using Polygenic Scores to Select Embryos
Why Complex Traits Resist Simple Selection
Intelligence illustrates the difficulty well. It is highly polygenic, meaning genome-wide studies have identified thousands of DNA variants each contributing a small effect. Polygenic scores can aggregate those effects, but they explain only a fraction of the variation observed in the population.7PubMed Central. Polygenic Scores for Cognitive Abilities and Their Association with Different Aspects of General Intelligence—A Deep Phenotyping Approach Twin studies show that intelligence is substantially heritable, yet no individual genetic variants have been robustly linked to normal-range intelligence; the heritability is distributed across a huge number of tiny contributions.8Intelligence. Mendelian and polygenic inheritance of intelligence: A common set of causal genes? Using next-generation sequencing to examine the effects of 168 intellectual disability genes on normal-range intelligence This stands in contrast to intellectual disability, which can involve large effects of single mutations.
Brain structure follows a similar pattern. Heritable variation in brain volume is substantial, with genetic factors explaining roughly half the variation in intracranial and total brain volume.9Cerebral Cortex. Polygenic Architecture of Human Neuroanatomical Diversity But that heritability is spread across so many loci that selecting for it in a practical setting, with a handful of embryos, would produce negligible shifts. The gap between “heritable” and “selectable” is vast, and the marketing of embryo screening products often obscures this distinction.
CRISPR and Germline Gene Editing
If screening embryos is the passive approach, gene editing is the active one. CRISPR/Cas9 technology has made it technically possible to alter DNA sequences in human embryos, either to knock out a disease-causing mutation or to introduce a specific correction.10Human Reproduction Update. Genome engineering through CRISPR/Cas9 technology in the human germline and pluripotent stem cells The path to genome editing has never been simpler or more affordable, which is precisely why it attracts so much concern.
Two major technical hurdles stand in the way of safe clinical use. The first is off-target effects: the editing tool sometimes cuts DNA at unintended sites, producing mutations elsewhere in the genome. Studies in human embryos have shown that off-target activity results in both insertions and deletions at unintended locations and segmental chromosomal changes, including losses of whole chromosome segments.11Cell. Heritable Human Genome Editing Directed by CRISPR/Cas9 Yields Complex Genomic Changes in Human Embryos The second is mosaicism: when an embryo is edited after the first cell division, some cells carry the edit while others do not, producing an organism with a patchwork genome.12PubMed Central. Evaluation of mutation rates, mosaicism and off target mutations when injecting Cas9 mRNA or protein for genome editing of bovine embryos Newer delivery strategies like ribonucleoprotein complexes and base editing have improved precision, but a fundamental trade-off between editing efficiency and mosaicism persists.13Biology of Reproduction. CRISPR-based genome editing in human embryos: a review of efficiency, safety, and ethical implications Before clinical applications should be considered, these hurdles need to be resolved.14Seminars in Cell & Developmental Biology. CRISPR/Cas gene editing in the human germline
The Pleiotropy Problem
Even if editing became perfectly precise, there is a deeper biological reason why engineering complex traits would be risky. Pleiotropy, where a single genetic variant affects multiple traits, is the norm in human genetics rather than the exception. A variant that protects against one disease can increase risk for another. GWAS data consistently show that large-effect variants tend to be rare, which suggests that natural selection has been weeding them out because their overall impact is harmful. Modeling studies indicate that inducing a large change in any one trait through editing is, on average, likely to be harmful to overall fitness.15Nature. Heritable polygenic editing: the next frontier in genomic medicine?
Positive selection for one trait over multiple generations could produce negative effects on other traits, and because variants associated with disease risk often play different roles at different developmental stages and in different cell types, eliminating them could have consequences no one can predict. Evolutionary genomics offers one framework for thinking about this: by distinguishing conserved, high-risk genetic targets from evolutionarily flexible ones, researchers hope to identify sites that are safer to modify.16PubMed Central. An evolutionary genomic perspective on preterm birth, genome editing, and pregnancy in the human species But for now, the practical upshot is that editing many genes at once to shift a complex trait would be a gamble with unpredictable stakes.
The Blurry Line Between Treatment and Enhancement
One of the persistent ethical flashpoints is where disease prevention ends and enhancement begins. Correcting a known mutation that causes sickle cell disease feels clearly therapeutic. Editing an embryo to resist a common infection falls into a gray zone. Tweaking variants associated with higher cognitive performance looks more like enhancement. These categories sound clean in the abstract but break down in practice, because prevention and enhancement occupy overlapping territory that is difficult to separate.17PubMed Central. Challenging the Boundaries Between Treatment, Prevention, and Enhancement in Human Genome Editing
Researchers have proposed the concept of “preventive strengthening research” to describe projects that strengthen individuals’ resistance to disease beyond what biomedicine considers the normal human functional range. If such projects are perceived as pursuing enhancement, they face heightened barriers to scientific, public, and regulatory approval, even when the intention is disease prevention.18PubMed Central. Preventive Human Genome Editing and Enhancement: Candidate Criteria for Governance The distinction matters because most regulatory frameworks and professional guidelines use the treatment-enhancement boundary to draw the line between what is permissible and what is not. If that boundary is fundamentally blurry, the governance frameworks built on top of it are unstable.
Procreative Beneficence and the Disability Rights Critique
The philosophical debate over selecting offspring traits often starts with the principle of procreative beneficence, articulated by bioethicist Julian Savulescu: parents should select the child, of the possible children they could have, who is expected to have the best life based on the relevant available information.19PubMed. Procreative beneficence: why we should select the best children On its face this sounds reasonable, maybe even obvious. But it runs headlong into a powerful counterargument from disability rights scholars and activists.
The disability rights critique holds that living with a disabling trait need not be detrimental to a person’s prospects of a worthwhile life, nor to their family or society. When prenatal testing and selective implantation are offered specifically to avoid disability, the practice sends a message that lives with disability are less worth living.20PubMed. Disability rights critique of prenatal genetic testing: reflections and recommendations This is sometimes called the “expressivist” objection, though disability scholars emphasize that their critique goes deeper than messaging alone and encompasses questions about social support, medical gatekeeping, and mistaken assumptions about quality of life.21Encyclopedia of Life Sciences. Disability and Genetics: A Disability Critique of Pre‐natal Testing and Pre‐implantation Genetic Diagnosis (PGD) Drawing on a social model of disability, these scholars argue that the problems associated with disability are largely constructed by a society that fails to accommodate difference, and that genetic technologies aimed at eliminating disability reinforce that failure rather than addressing it.22PubMed Central. Disability, Genetic Counseling, and Medical Education: From Eugenics to Anti-Ableism
Who Gets Access
Every reproductive genetic technology sits behind a financial gate. IVF itself costs thousands of dollars per cycle, and genetic testing adds to the bill. Population-level data from Australia show that access to assisted reproductive technology progressively decreases as socioeconomic status drops, with roughly a 16% decrease in access in the most disadvantaged group compared with the most advantaged after adjusting for factors like delayed childbearing and geographic remoteness.23PubMed. Socio-economic disparities in access to assisted reproductive technologies in Australia The pattern almost certainly holds in countries with less public funding for fertility treatment.
If genetic selection tools become more powerful over time, and access remains concentrated among wealthier families, the result could be a genetic stratification layered on top of existing economic stratification. This is not a new worry; it has been raised since the early days of PGT. But it has grown sharper as commercial polygenic screening companies market directly to consumers who can afford elective IVF, widening the gap between those who can choose their embryos’ genetic profiles and those who cannot.
The Consent Problem With Heritable Edits
Germline editing is distinct from every other medical intervention in one crucial way: changes to an embryo’s DNA are passed to all future descendants. The person most affected by the edit, the future child and their children, cannot consent to it. Roughly 80% of rare and often serious conditions affect newborns and children, and about half of all rare diseases are considered to have childhood onset. If heritable genome editing were proven safe, advocates argue it could be seen as a form of preventive medicine that fosters a child’s right to health, and that an arbitrary moratorium neither serves children’s best interests nor respects their right to benefit from scientific progress.24Mary Ann Liebert, Inc., publishers. Heritable Genome Editing: Who Speaks for “Future” Children?
Critics counter that this framing smuggles in an assumption: that the genetic change will unambiguously benefit the child. Given the problems of off-target effects, pleiotropy, and limited understanding of gene-environment interactions, that assumption is far from safe. The bioethics literature also raises a subtler point about autonomy. A heritable edit does not just affect one person; it constrains the genetic possibilities available to an entire lineage. The ethical weight of that constraint is difficult to measure, and there is no consensus on how to weigh a present parent’s desire to prevent disease against a future person’s right to an unedited genome. Traditional informed consent frameworks, built for competent adults making decisions about their own bodies, simply do not map onto this situation.
Epigenetic Inheritance Complicates the Picture
Most discussions of germline modification focus on DNA sequences, but heritable biology is not limited to genes. Sperm, eggs, and embryos carry epigenetic information, chemical tags and structural features that influence gene expression without changing the underlying DNA sequence, and there are indications that changes to these non-genetic structures can also be inherited across generations.25Bioethics. Blurring the germline: Genome editing and transgenerational epigenetic inheritance Treating “germline inheritance” and “genetic inheritance” as simple synonyms is a mistake. This means that even a perfectly targeted genetic edit could interact with epigenetic states in ways that are difficult to predict, and that the act of IVF itself, with its hormonal stimulation and laboratory culture conditions, may introduce epigenetic changes whose long-term effects remain unclear.
The Global Regulatory Patchwork
A survey of 106 countries found that 96 have policy documents, whether legislation, regulations, guidelines, or international treaties, relevant to genome editing of early human embryos, gametes, or their precursor cells. Of those countries with specific policies on laboratory research using genetically modified embryos, 23 prohibit the research and 11 explicitly permit it. Seventy-five of the 96 countries prohibit heritable genome editing, meaning the use of modified embryos to initiate a pregnancy. No country explicitly permits it.26PubMed. Human Germ Line and Heritable Genome Editing: The Global Policy Landscape
The 2018 case of He Jiankui, who secretly used CRISPR to edit the genomes of twin girls in China, served as a shock that strengthened precautionary positions worldwide and led to more restrictive national legislation. Yet despite this tightening, the lack of a unified international framework has produced regulatory fragmentation, where rules differ from country to country with no binding treaty coordinating them.27Politics. Global governance of human germline genome editing: An advocacy coalition framework analysis Comparing the approaches of China, the United States, and the United Kingdom reveals significant differences in how each country balances legislation, regulatory agencies, and public participation in governance.28PubMed Central. Regulatory framework of human germline and heritable genome editing in China: a comparison with the United States and the United Kingdom This fragmentation raises the prospect of “regulatory tourism,” where those with resources travel to jurisdictions with looser oversight to access technologies unavailable at home.
Mitochondrial Replacement and Other Edge Cases
Not all heritable genetic interventions fit neatly into the screening-versus-editing framework. Mitochondrial replacement therapy, sometimes called the “three-parent baby” technique, replaces defective mitochondria in a mother’s egg with healthy mitochondria from a donor. The nuclear genome, which contains the vast majority of a person’s genetic information, remains untouched. The goal is to prevent severe mitochondrial diseases, which are inherited exclusively through the maternal line. Techniques include pronuclear transfer, spindle transfer, polar body transfer, and germinal vesicle transfer. The United Kingdom legalized this approach in 2015, making it the first country to permit a form of heritable genetic modification in a clinical setting. The procedure raises many of the same ethical questions as germline editing, but with a narrower scope: it replaces a small set of energy-producing genes and does not alter traits like appearance or behavior.
In Vitro Gametogenesis on the Horizon
A technology that could dramatically expand the scope of genetic selection is in vitro gametogenesis, or IVG: the creation of eggs and sperm from ordinary body cells, via an intermediate stem cell stage. Researchers have already produced rudimentary human oocytes and sperm from pluripotent stem cells grown alongside mouse gonadal tissue. Most scientists do not anticipate IVG being used in human reproduction for at least a decade, and the genetic and epigenetic integrity of lab-derived gametes appears to be substantially lower than that of naturally produced ones.29PubMed Central. Pluripotent Stem Cell-Derived In Vitro Gametogenesis and Synthetic Embryos—It Is Never Too Early for an Ethical Debate
If IVG works, it would remove one of the natural constraints on embryo selection: the small number of eggs available per IVF cycle. With unlimited eggs, parents could generate hundreds of embryos and screen them extensively. That possibility would supercharge the power of polygenic screening, because the gains from selection increase with the number of embryos to choose from. It would also open reproduction to people who currently cannot produce gametes at all, including same-sex couples, postmenopausal women, and individuals who have lost gonadal function. The ethical implications are genuinely hard to foresee, which is why bioethicists have argued that an ethical debate should begin now, long before clinical application.
Religious and Cross-Cultural Perspectives
The ethics of genetic modification do not land the same way everywhere. Given the global impact of gene-editing technology, international regulatory bodies have emphasized the need for intercultural dialogue. Islamic bioethical discourse, for example, engages seriously with the boundaries between genetic treatment and enhancement, drawing on principles of necessity, harm prevention, and the concept of human stewardship over creation.30Journal of Religious Ethics. Between Treatment and Enhancement: Islamic Discourses on the Boundaries of Human Genetic Modification Many Islamic scholars accept therapeutic genetic intervention while remaining cautious about enhancement, though opinions differ across traditions and regions. Christian perspectives range from Catholic opposition to most embryo manipulation to more permissive Protestant views. Jewish bioethics tends to focus on the obligation to heal, sometimes reaching more permissive conclusions about genetic intervention than other traditions. None of these positions map cleanly onto the secular treatment-enhancement distinction, which makes international consensus-building especially challenging.